Biliary type-II sphincter of Oddi dysfunction with a pancreatic duct dilation: a case report and review of the literature

AlKhoury, Naseem; Mohamad, Okbah; Mazloum, Abd Al-Jawad; Madi, Maher

doi:10.1186/s13256-021-02674-z

Cited by 2 publications

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, the incidence of tumours in DDS incidentally found when associated with normal LFTs remains unclear, and the incidence is increasing due to the almost ubiquitous use of cross-sectional imaging. Benign causes for DDS were also reported including CBD stones [ 4 ], chronic pancreatitis [ 5 ], and sphincter of Oddi dysfunction [ 6 , 7 ]. DDS often results in multiple discussions at multidisciplinary team meetings (MDT) and further investigations including endoscopic ultrasound (EUS) and/or surveillance scans.…”

Section: Introductionmentioning

confidence: 99%

Clinical Significance and Resource Burden of Double Duct Sign in Non-jaundiced Patients

Mahmoud Askar,

Zahir Hussain,

Chavda

et al. 2024

Cureus

View full text Add to dashboard Cite

Aim The study aims to determine the incidence of malignancy at presentation and subsequent risk of malignancy (at 12 months follow-up) in a cohort of patients with double duct sign (DDS) on cross-sectional imaging but no visible stigmata of jaundice. The study also correlates malignancy with liver enzyme dysfunction and estimates the resource burden incurred during the investigation of these patients. Methods A search for the key term "double duct sign" was undertaken in the radiological database of a tertiary hepatopancreatobiliary (HPB) centre between March 2017 and March 2022. Radiological reports, clinic letters, blood results, and multidisciplinary team meeting (MDT) outcomes were reviewed during this period and at one year. The national tariff payment system was reviewed to identify tariffs for different investigations required for the cohort and to calculate the total cost incurred. Results Ninety-seven patients with DDS were identified. Sixty-four patients (66%) had a normal bilirubin (0-21 µmol/L) at presentation and were included in the analysis. Seven patients (10.9%) were diagnosed with malignant peri-ampullary tumours, and 21 (32.8%) were diagnosed with benign diseases. In 34 patients (53%) with DDS, the underlying cause remained uncharacterised. Most patients had mild abnormalities of liver enzymes, but two patients (4.3%) were diagnosed with malignant peri-ampullary tumours despite having normal serological values. Patients who had a benign diagnosis and/or who had cancer excluded without a definitive diagnosis did not go on to develop a malignancy at 12 months follow-up. However, in those patients where the underlying aetiology could not be characterised, extended surveillance was required with a total of 80 MDT discussions and multiple surveillance scans (103 CT and 65 MRI scans). Twenty-six patients underwent endoscopic ultrasound (EUS) with three patients requiring more than one EUS examination (29 investigations in total). The cost of these investigations was £38,926.89. Conclusion This study confirms that DDS even in patients without clinical jaundice or with normal liver enzymes requires careful investigation to exclude malignancy despite the resource burden this entails. This supports previously reported results in the literature, and despite the increased use of cross-sectional imaging, DDS remains a clinically significant finding. Large cohort risk stratification studies would be useful to determine clinical urgency and allow the appropriate allocation of resources.

show abstract

Section: Introductionmentioning

confidence: 99%